Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EHA 2021

Latest Videos

View all
1:26
Ruxolitinib plus venetoclax for T-PLL: rationale and findings
Charles Herbaux • 25 May 2021
1:42
Exciting myeloma updates coming soon at EHA 2021
Enrique Ocio • 26 May 2021
2:52
Outcomes of haplo-TBF versus MUD-FB in AML
Ali Bazarbachi • 25 May 2021
2:15
The management of multiple myeloma in 2021
Claudio Cerchione • 25 May 2021

Multiple Myeloma

View all
1:41
ANCHOR: novel melflufen combinations in R/R myeloma
Enrique Ocio • 26 May 2021
2:53
MRD evaluation during ixazomib maintenance in myeloma
Bruno Paiva • 28 May 2021
2:51
18-month follow-up on CARTITUDE-1
Saad Usmani • 2 Jun 2021
2:38
Updates on belantamab mafodotin for myeloma
Claudio Cerchione • 25 May 2021

Lymphoma

View all
3:33
TG-1701: monotherapy & combination with U2 for CLL and lymphoma
Chan Yoon Cheah • 26 May 2021
1:46
Atezolizumab-obinutuzumab-venetoclax in follicular lymphoma and MZL
Charles Herbaux • 25 May 2021

CLL

View all
2:21
Outcomes of TP53-disrupted CLL patients treated with frontline ibrutinib
Andrea Visentin • 1 Jun 2021
4:11
IMPROVE: 33-month follow-up of MRD-driven therapy in CLL
Lydia Scarfò • 28 May 2021

ALL

View all
3:19
Blinatumomab plus ponatinib for Ph+ ALL
Nicholas Short • 25 May 2021
5:23
Redefining low risk high hyperdiploidy in pediatric ALL
Anthony Moorman • 8 Jun 2021

AML

View all
3:04
FF-10101-01: a novel FLT3 inhibitor for R/R AML
Mark Levis • 27 May 2021
3:00
KOMET-001: targeting menin-KMT2A in AML
Eunice Wang • 27 May 2021

MDS

View all
1:06
COMMANDS trial: luspatercept vs epoetin alfa in lower-risk MDS
Uwe Platzbecker • 1 Jun 2021
2:10
Updated overall survival data on eltanexor for HMA-refractory MDS
Sangmin Lee • 4 Jun 2021

MPNs

View all
1:49
Results from MANIFEST Phase II study of pelabresib for anemia associated with myelofibrosis
Srdan Verstovsek • 9 Jun 2021
1:27
JAKARTA and JAKARTA2: OS and PFS analysis of fedratinib in myelofibrosis
John Mascarenhas • 10 Jun 2021

Transplantation

View all
6:57
Downregulation of HLA expression in acute leukemia relapsed after transplantation
Hui Wang • 17 Jun 2021
4:33
INTEGRATE: 2-year follow-up of ibrutinib plus corticosteroids for cGvHD
David Miklos • 14 Jun 2021
2:26
Outcomes with RIC before second HSCT in secondary AML
Arnon Nagler • 14 Jun 2021
1:19
Narsoplimab increases platelets and decreases LDH in TA-TMA
Eleni Gavriilaki • 26 May 2021

Immuno-Oncology

View all
4:47
Sabatolimab plus HMAs in high-/very high-risk MDS and ND-AML
Andrew Brunner • 3 Jun 2021
1:40
ELEVATE-TN: 4-year follow-up shows PFS benefit of A or A+O over O+Clb for CLL
John Byrd • 3 Jun 2021

CAR-T & Cellular Therapies

View all
6:24
ZUMA-3 study update: brexucabtagene autoleucel for R/R ALL
Bijal Shah • 2 Jun 2021
3:22
CD20 targeted CAR-T: MB-106 in B-NHL and CLL
Mazyar Shadman • 25 May 2021

Latest Podcasts

Key updates on CAR-T & cellular therapy for AML
Key updates on CAR-T & cellular therapy for AML
Latest updates in Hodgkin lymphoma from ISHL HL 2021
Latest updates in Hodgkin lymphoma from ISHL HL 2021
Post-EBMT highlights in acute myeloid leukemia
Post-EBMT highlights in acute myeloid leukemia
Updates for the management of MDS from ASH 2020
Updates for the management of MDS from ASH 2020
The content of VJHemOnc is intended for healthcare professionals